All News
Which biologic will you use after MTX and TNF failure for RA pts? #acr20 @rheumnow
k dao KDAO2011 ( View Tweet)
Amazing lecture by Dr Jane Salmon for the RRF memorial foundation to honor Dr Shaun Ruddy #ACR20 @HSpecialSurgery @RheumNow the IMPACT study - pregnancy in APS with Certolizumab Therapy https://t.co/A9U11qI7zG
Bella Mehta bella_mehta ( View Tweet)
#ACR20 Abs#L11. Efficacy of TOFA vs PBO in AS. At week 16, %ASAS20 responders 56% v 29% PBO; %ASAS40 40% vs 12%. @RheumNow #ACRBest https://t.co/3Faj64rBjd
Eric Dein ejdein1 ( View Tweet)
Following RITAZAREM, would you use rituximab maintenance for ANCA-associated vasculitis patients (cost aside)? @RheumNow
David Liew drdavidliew ( View Tweet)
Improvement of enthesitis US scores consistent with bDMARD initiation/change
1⃣MASEI and OMERACT scores improved at 3 mo/6mo
2⃣Associated with clinical activity outcomes
@RheumNow #ACR20 Abs#1552 https://t.co/qnSEBaXrJo
Robert B Chao, MD doctorRBC ( View Tweet)
RITZAREM
(RTX vs AZA maintenance post RTX induction relapsing AAV)
what happened post-study?
After #ACR19, hope RTX confers ongoing benefit
Answer: no. Same decline
Is 1g q4m dosing not justified?
Does that mean RTX needs to be continued, and in whom?
#ACR20 ABST2052 @RheumNow https://t.co/tldGqca8xC
David Liew drdavidliew ( View Tweet)
Rheum Now shares Day 3 highlights from #ACR20.
https://t.co/xNv1fG97ib https://t.co/Psa8bRqlVh
Links:
Dr. John Cush RheumNow ( View Tweet)
RITAZAREM trial long-term follow-up
-RTX vs AZA after RTX-induced remission in ANCA #vasculitis
-RTX superior to AZA to prevent relapse
-Relapse common regardless of therapy; high-dose RTX not effective beyond treatment period
Abs#2052 #ACR20 @RheumNow
https://t.co/bW7IaMnVCG
Mrinalini Dey DrMiniDey ( View Tweet)
Fantastic session about the 2020 guidelines for management of RA! Soon to be published.
One major difference from 2015 guidelines ➡️ Conditional recommendation to choose a Biologic over Triple Therapy in MTX-inadequate responders (Discussion about patient preference is key!) https://t.co/s016piIN7Q
Dr. Tina Mahajan drtinamahajan ( View Tweet)
SLR comparing the 4-dose ANCA #vasculitis (AAV) rituximab regimen (widely used in RCTs) to 2-dose #rheumatoidarthritis RTX regimen (common in clinical practice), to induce AAV remission, finds no difference in efficacy or safety.
Abs#2048 #ACR20 @RheumNow
https://t.co/WBaWN9d8vs
Mrinalini Dey DrMiniDey ( View Tweet)
Upadacitinib vs. Adalimumab vs. PBO in PsA Phase 3 RCT ⬇️MSK symptoms, PsO, function, pain, fatigue, rads progression in UPA *⃣UPA15 non-inferior to ADA for ACR20, UPA30 superior *⃣Similar VTE in all arms @RheumNow #ACR20 Abs#2026 https://t.co/OHzIjXKqAu
Robert B Chao, MD doctorRBC ( View Tweet)
Conditional recommendation to add bDMARD or tsDMARD in RA pts on maximally tolerated dose of MTX over adding HCQ+SSZ (triple therapy) per draft recommendation of new ACR RA treatment guidelines. #ACR20 @RheumNow @ElaineHusniMD https://t.co/MW0fOAeK09
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Draft #ACR20 Rx Recs for RA: on max tolerated MTX - add bio or tsDMARD conditional recommendation over triple therapy (MTX, HCQ, SSZ). @RheumNow. https://t.co/s6fKEW8czc
Eric Dein ejdein1 ( View Tweet)
Draft #ACR20 Rx Recommendations for RA: MTX monotherapy conditionally rec over csDMARD dual or triple Rx, MTX+TNFi @RheumNow https://t.co/jyjRD5aadN
Eric Dein ejdein1 ( View Tweet)
Rituximab in AAV: how to dose?
Should we be giving:
- 'haem dosing': 375mg/m2 x4 doses
- 'RA dosing': 1000mg x2 doses
Systematic review says: no difference
Reassuring given the variation in practice in real life!
#ACR20 ABST2048 @RheumNow https://t.co/Jf4Ue6HRRL
David Liew drdavidliew ( View Tweet)
Dr Benard reports an SLR and meta-analysis of 27 studies comparing 2 rituximab regimes in AAV. 375mg x4 and 1000mg x2 equivalent. Remission in 91% vs 85%. Similar adverse event rates @rheumnow #ACR20 Abstr#2048 https://t.co/I0feVuZ8iy
Richard Conway RichardPAConway ( View Tweet)
Anakinra in #Stills disease - Double blind, placebo controlled RCT in Stills disease total 12pts, 6 placebo, 6 Rx grp. All pts reached ACR70 at week 2 without fever and sustained it at 12 weeks. 5/6 reached ACR90 @RheumNow
#ACR20 ABS#1633 #ACRbest https://t.co/9E4vm7WzhP
Bella Mehta bella_mehta ( View Tweet)
Wonder if you can predict which pts you can successfully taper off bDMARDs? Abst#1538 from Denmark showed that a neg IgM-RF (OR 0.26) & low Doppler serum score for 24 jts predicted successful discontinuation of bDMARDs at 2yr f/u in RA pts w/ DAS28-CRP<2.6. #ACR20 @RheumNow https://t.co/CbJTguxaoa
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Abatacept in RA and ILD Patients: Dr Richard Conway (@RichardPAConway) #ACR20
https://t.co/e31VsnXFq5 https://t.co/sCrqLtXFFc
Links:
Dr. John Cush RheumNow ( View Tweet)
#FDA updates #ACR20 @rheumnow
labeling/warning changes:
belimumab- mortality removed
abatacept - angioedema added
baricitinib -hypersensitivity rxn added
gabapentin & pregabalin - respiratory depression added
k dao KDAO2011 ( View Tweet)
